Pharmaceutical Preparations · DE · CIK 1768446
Developing potential best-in-class therapeutics for immune-mediated diseases by targeting CD19-positive B cells
Comparable business profile · signals at a glance
In the 90 days to Feb 26, 2026: 2 insiders bought $780K · 1 sold $879K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 26, 2026 | Thomas Stephen BasilDirector | Sell | 16,313 | $7.01 | $114K |
| Feb 25, 2026 | Thomas Stephen BasilDirector | Sell | 33,687 | $7.00 | $236K |
| Feb 13, 2026 | Thomas Stephen BasilDirector | Sell | 10,000 | $5.81 | $58K |
| Feb 12, 2026 | Thomas Stephen BasilDirector | Sell | 90,000 | $5.23 | $471K |
| Jan 5, 2026 | Ra Capital Healthcare Fund LpDirector,TenPercentOwner | Buy | 7,111 | $3.50 | $25K |
| Dec 12, 2025 | Kolchinsky PeterDirector,TenPercentOwner | Buy | 101,462 | $2.86 | $290K |
| Dec 11, 2025 | Kolchinsky PeterDirector,TenPercentOwner | Buy | 213,099 | $2.18 | $465K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.